OncoCyte, Corp. (Nasdaq: OCX), a precision diagnostics company, has recently released new data that demonstrates the effectiveness of VitaGraft Kidney in aiding physicians in treating kidney transplant patients with greater precision. The study focused on differentiating between two common causes of premature graft failure: antibody-mediated rejection (ABMR) and recurrent IgA nephropathy (IgAN)...
IntelGenx Corp. has recently announced a groundbreaking research collaboration with Karolinska University Hospital. The focus of this collaboration is to explore the potential of using Montelukast VersaFilm® as a treatment for Parkinson's Disease. Led by the esteemed Professor Per Svenningsson, an expert in clinical neuroscience, this study will delve into the efficacy of IntelGenx's innovative ..
Crescendo Biologics, a clinical stage immuno-oncology company, has secured an additional $32 million in funding. This capital infusion was made possible through the support of all major existing investors and new investor Kreos Capital. In conjunction with this exciting news, Crescendo has announced its plans to expand the Phase 1b trial of their lead program CB307 in PSMA+ solid tumors by intro..
Orthogon Therapeutics Celebrates Major Technical Milestone and Secures Additional $6M Toward a Pioneering Drug for BK Virus Published: Jul 24, 2023 In an exciting development, Orthogon Therapeutics LLC, a leading player in the field of antiviral therapeutics, has achieved a significant breakthrough. The company's flagship molecule has successfully completed acute toxicity studies, marking a majo..
DiaCarta Inc., a leading molecular diagnostic test developer for cancer and infectious diseases, has announced a strategic partnership with Hopkins MedTech Compliance (HMC) and Hopkins MedTech Lab Services (HML) to address the regulatory compliance and laboratory developed test (LDT) validation needs in the United States. This collaboration aims to provide support to companies that have develope..
Enveric Biosciences (NASDAQ: ENVB) has announced positive findings from preclinical studies that support the metabolic profile of its leading candidate, EB-373. The absorption, distribution, metabolism, and excretion (ADME) as well as toxicology assays have demonstrated rapid conversion of EB-373 to the active metabolite psilocin. These results are consistent with previous animal pharmacokinetic..